BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 27276368)

  • 1. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
    Thrift AP
    Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barrett's esophagus and risk of esophageal adenocarcinoma.
    Cossentino MJ; Wong RK
    Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
    Wang F; Lv ZS; Fu YK
    Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
    Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
    Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Present Status and Future of Barrett's Esophageal Adenocarcinoma in Japan.
    Nishi T; Makuuchi H; Ozawa S; Shimada H; Chino O
    Digestion; 2019; 99(2):185-190. PubMed ID: 30481763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
    Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
    Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.
    Runge TM; Abrams JA; Shaheen NJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):203-31. PubMed ID: 26021191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Acid Suppression in Barrett's Esophagus.
    Elias PS; Castell DO
    Am J Med; 2017 May; 130(5):525-529. PubMed ID: 28159599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
    Thrift AP; Anderson LA; Murray LJ; Cook MB; Shaheen NJ; Rubenstein JH; El-Serag HB; Vaughan TL; Schneider JL; Whiteman DC; Corley DA
    Am J Gastroenterol; 2016 Nov; 111(11):1528-1535. PubMed ID: 27575711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rat Reflux Model of Esophageal Cancer and Its Implication in Human Disease.
    Greene CL; Worrell SG; DeMeester TR
    Ann Surg; 2015 Dec; 262(6):910-24. PubMed ID: 25822684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of Barrett's esophagus: can it prevent cancer?
    Sampliner RE
    Surg Oncol Clin N Am; 2009 Jul; 18(3):503-8. PubMed ID: 19500739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
    Dunbar KB; Souza RF; Spechler SJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for Barrett's esophagus.
    Rubenstein JH
    Curr Opin Gastroenterol; 2014 Jul; 30(4):408-14. PubMed ID: 24859804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Barrett's esophagus and esophageal adenocarcinoma.
    Shaheen NJ
    Gastroenterology; 2005 May; 128(6):1554-66. PubMed ID: 15887151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction.
    Pera M
    World J Surg; 2003 Sep; 27(9):999-1008; discussion 1006-8. PubMed ID: 12917764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
    Bresalier RS
    Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barrett's esophagus: A comprehensive review for the internist.
    Klavan H; Russell MB; Macklin J; Lee E; Aslanian HR; Muniraj T
    Dis Mon; 2018 Nov; 64(11):471-487. PubMed ID: 29880269
    [No Abstract]   [Full Text] [Related]  

  • 18. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
    Tan MC; El-Serag HB; Yu X; Thrift AP
    Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
    Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
    Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.